Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNG | P07510 | 1/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRND | Q07001 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18091638 | 0.88 | OPRM1 (0.38) | OPRM1SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL4699751 | 0.83 | OPRM1 (0.40) | OPRM1SLC6A2SLC6A3SLC6A4CHRNB2 | |
| SCHEMBL4702618 | 0.81 | OPRM1 (0.52) | OPRM1 | |
| SCHEMBL4703423 | 0.70 | OPRM1 (0.54) | OPRM1SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL4698128 | 0.70 | OPRM1 (0.54) | OPRM1SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL4698125 | 0.65 | OPRM1 (0.57) | OPRM1 | |
| SCHEMBL16591307 | 0.65 | SLC6A3 (0.36) | SLC6A2SLC6A3SLC6A4CHRNA1CHRNG | |
| SCHEMBL18091478 | 0.64 | OPRM1 (0.37) | OPRM1 | |
| SCHEMBL6024070 | 0.64 | OPRM1 (0.76) | OPRM1 | |
| SCHEMBL3542153 | 0.60 | CHRNA1 (0.35) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1440059-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070054950-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | PFIZER INC. | 2007-03-08 | — | — | US | disclosed |
| US-7049335-B2 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20050171178-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| EP-1440059-A1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20030087898-A1 | 3-azabicyclo[3.1.0]hexane derivatives | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2003035622-A1 | 3-AZABICYCLO (3.1.0) HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087898-A1 | 3-azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885SLC6A2 2828/4885SLC6A3 1359/4885 |
| US-20050171178-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885SLC6A2 2353/4885SLC6A3 918/4885 |
| US-20070054950-A1 | 3-Azabicyclo[3.1.0]hexane derivatives | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885SLC6A2 2579/4885SLC6A3 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.